These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 34379729)

  • 1. T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease.
    Reuken PA; Andreas N; Grunert PC; Glöckner S; Kamradt T; Stallmach A
    J Crohns Colitis; 2022 Feb; 16(2):251-258. PubMed ID: 34379729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
    Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
    Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
    Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U
    Front Immunol; 2022; 13():889138. PubMed ID: 35634285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
    Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
    J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
    Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
    Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
    EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
    Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ
    Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Bordalo Ferreira F; Rafael MA; Coimbra L; Boavida N; Arrobas F; Pereira Correia F; Martins Figueiredo L; Carvalho E Branco J; Carvalho Lourenço L; Santos L; Oliveira AM
    Vaccine; 2023 Jun; 41(26):3862-3871. PubMed ID: 37202269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.
    Vollenberg R; Tepasse PR; Lorentzen E; Nowacki TM
    J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8
    van den Dijssel J; Duurland MC; Konijn VA; Kummer LY; Hagen RR; Kuijper LH; Wieske L; van Dam KP; Stalman EW; Steenhuis M; Geerdes DM; Mok JY; Kragten AH; Menage C; Koets L; Veldhuisen B; Verstegen NJ; van der Schoot CE; van Esch WJ; D'Haens GR; Löwenberg M; Volkers AG; Rispens T; Kuijpers TW; Eftimov F; van Gisbergen KP; van Ham SM; Ten Brinke A; van de Sandt CE;
    J Autoimmun; 2024 Apr; 144():103175. PubMed ID: 38387105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
    Zacharopoulou E; Orfanoudaki E; Tzouvala M; Tribonias G; Kokkotis G; Kitsou V; Almpani F; Christidou A; Viazis N; Mantzaris GJ; Tsafaridou M; Karmiris K; Theodoropoulou A; Papathanasiou E; Zampeli E; Michopoulos S; Tigkas S; Michalopoulos G; Laoudi E; Karatzas P; Mylonas I; Kyriakos N; Liatsos C; Kafetzi T; Theocharis G; Taka S; Panagiotopoulou K; Koutroubakis IE; Bamias G
    Inflamm Bowel Dis; 2023 Feb; 29(2):228-237. PubMed ID: 35394529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
    Doherty J; Morain NO; Stack R; Girod P; Tosetto M; Inzitiari R; Sheridan J; Cullen G; McDermott E; Buckley M; Horgan G; Mulcahy H; Ryan EJ; Daghfal D; Doran P; Morain CO; Doherty GA
    J Crohns Colitis; 2022 Sep; 16(9):1354-1362. PubMed ID: 35176770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.
    Caldera F; Farraye FA; Necela BM; Cogen D; Saha S; Wald A; Daoud ND; Chun K; Grimes I; Lutz M; Van Helden SR; Swift MD; Virk A; Bharucha AE; Patel TC; Gores GJ; Chumsri S; Hayney MS; Knutson KL
    Inflamm Bowel Dis; 2023 Aug; 29(8):1202-1209. PubMed ID: 36103273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
    Alexander JL; Moran GW; Gaya DR; Raine T; Hart A; Kennedy NA; Lindsay JO; MacDonald J; Segal JP; Sebastian S; Selinger CP; Parkes M; Smith PJ; Dhar A; Subramanian S; Arasaradnam R; Lamb CA; Ahmad T; Lees CW; Dobson L; Wakeman R; Iqbal TH; Arnott I; Powell N;
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):218-224. PubMed ID: 33508241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.
    Wellens J; Colombel JF; Satsangi JJ; Wong SY
    J Crohns Colitis; 2021 Aug; 15(8):1376-1386. PubMed ID: 33721882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease.
    Brenner EJ; Weaver KN; Zhang X; Kastl AJ; Strople JA; Adler J; Dubinsky MC; Bousvaros A; Watkins R; Dai X; Chen W; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda EA; Farraye FA; Chun KY; Zikry M; Bastidas M; Firestine A; Craig RG; Boccieri ME; Long MD; Kappelman MD
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1475-1486.e4. PubMed ID: 38369224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease.
    Elkharsawi A; Arnim UV; Schmelz R; Sander C; Stallmach A; Teich N; Walldorf J; Reuken PA
    Z Gastroenterol; 2022 Jan; 60(1):77-80. PubMed ID: 35042256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey.
    Ellul P; Revés J; Abreu B; Chaparro M; Gisbert JP; Allocca M; Fiorino G; Barberio B; Zingone F; Pisani A; Cassar D; Michalopoulos G; Mantzaris G; Koutroubakis I; Karmiris K; Katsanos K; Ďuricova D; Burisch J; Madsen GR; Maaser C; Naila A; Orfanoudaki E; Milivojevic V; Buisson A; Avedano L; Leone S; Torres J
    J Crohns Colitis; 2022 Aug; 16(7):1070-1078. PubMed ID: 35037033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease.
    Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC
    Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.